Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years-Reference-Cited by-同舟云学术

Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years

Published:2012-02-19 Issue:8 Volume:44 Page:566-572
ISSN:0036-5548
Container-title:Scandinavian Journal of Infectious Diseases
language:en
Short-container-title:Scandinavian Journal of Infectious Diseases

Author:

Lind Andreas,Sommerfelt Maja,Holmberg Jens Olof,Baksaas Ingebjørg,Sørensen Birger,Kvale Dag

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/00365548.2011.653581

Reference16 articles.

1. Immunology and the elusive AIDS vaccine

2. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

3. Phase I Trial of a Therapeutic HIV Type 1 Vaccine, Vacc-4x, in HIV Type 1-Infected Individuals with or without Antiretroviral Therapy

4. Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control

5. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral T-cell epitopes – Identification, characterization and clinical application;Seminars in Immunology;2023-03

2. Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2;Journal of General Virology;2022-01-11

3. Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption;PLOS ONE;2019-01-30

4. Effect of the Modification of p24 Peptide Antigen on Dendritic Cell Uptake and T Cell Activation;Current HIV Research;2017-01-20

5. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial;Retrovirology;2016-06-09